Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis. There's no cure for primary biliary cholangitis, but medications are available to help slow the progression of the disease and prevent complications. Options include: Ursodeoxycholic acid (UDCA) and Obeticholic acid (Ocaliva).
This report contains market size and forecasts of Primary Biliary Cholangitis Treatment in Global, including the following market information:
Global Primary Biliary Cholangitis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Primary Biliary Cholangitis Treatment market was valued at 673.1 million in 2021 and is projected to reach US$ 2371.9 million by 2028, at a CAGR of 19.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Ursodeoxycholic Acid (UDCA) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Primary Biliary Cholangitis Treatment include Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Teva Pharmaceutical, Retrophin, Lumena Pharmaceuticals and Intercept Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Biliary Cholangitis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Biliary Cholangitis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Primary Biliary Cholangitis Treatment Market Segment Percentages, by Type, 2021 (%)
Ursodeoxycholic Acid (UDCA)
Obeticholic Acid (Ocaliva)
Global Primary Biliary Cholangitis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Primary Biliary Cholangitis Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Primary Biliary Cholangitis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Primary Biliary Cholangitis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Biliary Cholangitis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Primary Biliary Cholangitis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Teva Pharmaceutical
Retrophin
Lumena Pharmaceuticals
Intercept Pharmaceuticals